<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Human Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines give rise to progressively growing subcutaneous <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> in athymic mice </plain></SENT>
<SENT sid="1" pm="."><plain>These <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> are induced to regress by inoculation of Epstein-Barr virus-immortalized <z:mpath ids='MPATH_458'>normal</z:mpath> human lymphocytes </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, analysis of profiles of murine cytokine/chemokine gene expression in <z:e sem="disease" ids="C0006413" disease_type="Neoplastic Process" abbrv="BL">Burkitt tumor</z:e> tissues excised from the <z:mp ids='MP_0003815'>nude</z:mp> mice showed that expression of the murine alpha-chemokine interferon-inducible protein-10 (IP-10) was higher in the regressing than in the progressive <z:e sem="disease" ids="C0006413" disease_type="Neoplastic Process" abbrv="BL">Burkitt tumors</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We tested the effects of IP-10 on <z:e sem="disease" ids="C0006413" disease_type="Neoplastic Process" abbrv="BL">Burkitt tumor</z:e> growth in <z:mp ids='MP_0003815'>nude</z:mp> mice </plain></SENT>
<SENT sid="4" pm="."><plain>Inoculation of established <z:e sem="disease" ids="C0006413" disease_type="Neoplastic Process" abbrv="BL">Burkitt tumors</z:e> either with crude preparations of murine IP-10 or with purified human IP-10 caused visible <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> in a proportion of the animals, although no complete <z:mp ids='MP_0010537'>tumor regressions</z:mp> were observed </plain></SENT>
<SENT sid="5" pm="."><plain>Constitutive expression of murine IP-10 in Burkitt cells reduced their ability to grow as subcutaneous <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, and caused visible <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> in a proportion of the animals </plain></SENT>
<SENT sid="6" pm="."><plain>Histologically, IP-10-treated and IP-10-expressing <z:e sem="disease" ids="C0006413" disease_type="Neoplastic Process" abbrv="BL">Burkitt tumors</z:e> had widespread evidence of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue <z:mp ids='MP_0001651'>necrosis</z:mp> and of capillary damage, including intimal thickening and vascular <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>Thus, IP-10 is an antitumor agent that promotes damage in established <z:e sem="disease" ids="C1658953" disease_type="Neoplastic Process" abbrv="">tumor vasculature</z:e> and causes tissue <z:mp ids='MP_0001651'>necrosis</z:mp> in human Burkitt <z:hpo ids='HP_0002665'>lymphomas</z:hpo> established subcutaneously in athymic mice </plain></SENT>
</text></document>